22:50 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies suggest CAR T cell therapies targeting CEACAM5 could help treat neuroendocrine prostate cancer. Bioinformatics analysis of 7,555 human cell surface proteins, and transcriptomic and proteomic analyses of eight human...
22:53 , Apr 23, 2018 |  BC Extra  |  Preclinical News

CAR T against cell surface proteins to treat prostate cancer

Researchers at University of California Los Angeles identified cell surface targets to treat prostate adenocarcinoma and neuroendocrine prostate cancer, two distinct major subtypes of advanced prostate cancer, and suggested that CAR T cell therapy against...
19:19 , Jun 2, 2017 |  BC Week In Review  |  Company News

Sanofi, Immunogen amend financials of ADC deals

In exchange for $30 million, ImmunoGen Inc. (NASDAQ:IMGN) and Sanofi (Euronext:SAN; NYSE:SNY) eliminated potential milestone and royalties payments the biotech was eligible to receive under two deals involving five compounds. The candidates are isatuximab, SAR408701...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

Labetuzumab govitecan: Additional Phase I/II data

Interim data from 38 evaluable mCRC patients previously treated with >=1 irinotecan-containing regimen in the Phase II portion of an open-label, dose-escalation, U.S. Phase I/II trial showed that once-weekly 8 mg/kg IMMU-130 led to a...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

Labetuzumab govitecan: Phase I/II data

Data from 66 evaluable mCRC patients previously treated with >=1 irinotecan-containing regimen in an open-label, dose-escalation, U.S. Phase I/II trial showed that once- and twice-weekly IMMU-130 for the first 2 weeks of a 3-week cycle...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Clinical News

Labetuzumab-SN-38: Phase II started

Immunomedics began an open-label Phase II trial to evaluate IMMU-130 given every 2 weeks for 24 weeks in about 50 patients with metastatic colorectal cancer who have been previously treated with >=1 prior irinotecan-containing regimen....
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Labetuzumab-SN-38: Interim Phase I data

Interim data from 11 patients with metastatic colorectal cancer in an open-label, dose-escalation, U.S. Phase I trial showed that 2, 4, 8 and 16 mg/kg doses of labetuzumab-SN-38 every 2 weeks were generally well tolerated....
07:00 , Aug 29, 2011 |  BC Week In Review  |  Clinical News

Labetuzumab-SN-38: Phase I started

Immunomedics disclosed in its fiscal year 2011 earnings ending June 30 that it began an open-label, dose-escalation Phase I trial evaluating IV labetuzumab-SN-38 every 2 weeks in about 24 patients. Immunomedics Inc. (NASDAQ:IMMU), Morris Plains,...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

Neogenix Oncology preclinical data

In mouse xenograft models of solid tumors, NEO-201 significantly reduced tumor growth vs. a control IgG antibody (p=0.0034). NEO-201 is human mAb that the company said appears to target a variant of carcinoembryonic antigen (CEA)-related...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Clinical News

ICT-109: Pilot trial data

A pilot study of blood samples from 61 lung cancer patients and 66 healthy subjects showed that ICT-109 was able to distinguish between cancerous and non-cancerous samples (p=0.00002). ImmunoCellular Therapeutics Ltd. (OTCBB:IMUC), Los Angeles, Calif....